Quest for the right Drug
מידודרין הידרוכלוריד מורנינגסייד 2.5 מ"ג MIDODRINE HYDROCHLORIDE MORNINGSIDE 2.5 MG (MIDODRINE HYDROCHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Posology Initial dose: 2.5 mg three times a day. Depending on the results of supine and standing blood pressure recordings, this dose may be increased weekly up to a dose of 10 mg three times a day. This is the usual maintenance dosage. A careful evaluation of the response to treatment and of the overall balance of the expected benefits and risks needs to be undertaken before any dose increase and advice to continue therapy for long periods. The last daily dose should be taken at least 4 hours before bedtime in order to prevent supine hypertension (see also section 4.4). Midodrine Hydrochloride Morningside 2.5 mg tablets may be taken with food (see section 5.2). Paediatric population The safety and efficacy of midodrine hydrochloride in children and adolescents under the age of 18 years have not been established. No data are available. Elderly population There is limited data on dosing in the elderly and there are no specific studies which have focused on a possible dose reduction in the elderly population. Cautious dose titration is recommended. Patients with renal impairment There are no specific studies that have focused on a possible dose reduction in patients with renal impairment. Typically, midodrine hydrochloride is contraindicated in patients with acute renal impairment and severe renal impairment (see section 4.3). Patients with hepatic impairment There are no specific studies in this patient population (see also section 4.4). Method of administration For oral use.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף